Arovella Therapeutics Limited (ALA) Price & Analysis

Compare

18 Followers

ALA Stock Chart & Stats

AU$0.08

AU$0.00(0.00%)

At close: Jan 07 4:00 PM EST

AU$0.08

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.07 - AU$0.20

Previous CloseN/A

Volume194.12K

Average Volume (3M)1.58M

Market Cap

AU$102.61M

Enterprise ValueAU$86.47M

Total Cash (Recent Filing)AU$19.37M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta1.41

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding1,207,183,700

10 Day Avg. Volume1,549,358

30 Day Avg. Volume1,578,675

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)5.47

Price to Sales (P/S)806.87

P/FCF Ratio-14.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet; Essentially No DebtSustained near-zero debt and a materially stronger equity base reduce insolvency and interest risk, giving management time and optionality to advance clinical programs. Low leverage supports durable financial flexibility for R&D spending without immediate refinancing pressure.

Focused Immunotherapy/CAR Platform R&DA clear, specialized platform strategy in CAR/cell therapies is a structural strength: platform technologies can generate multiple candidates, create technical barriers to entry, and align investor and partner interest. This focused R&D model supports long-term value if clinical milestones are met.

Gross-profit Improvement; Cash Burn Tracks Accounting LossesA move to positive gross profit signals operational improvements at the program level, while free cash flow tracking net loss implies transparency and predictability in cash burn. Together these reduce the likelihood of hidden cash drains and support more reliable planning for capital needs.

Bears Say

Persistent, Large Operating LossesSustained operating losses erode equity and require ongoing external funding to sustain operations and trials. Over a 2-6 month horizon, continued negative margins increase dilution risk and constrain ability to invest selectively in programs or scale successful candidates without securing new capital.

Consistently Negative Operating And Free Cash FlowOngoing negative cash generation creates structural financing dependency. Even with low debt, persistent cash burn forces repeated capital raises or partnerships, which can dilute shareholders and divert management focus away from science toward fundraising over the coming months.

Highly Volatile, Minimal Revenue BaseA tiny, unstable revenue base prevents self-funding and undermines margin scalability; sharp year-over-year declines amplify reliance on external capital and partners. Structural dependence on financing increases execution risk if markets or partner interest weaken.

Arovella Therapeutics Limited News

Arovella Therapeutics Announces Departure of Director Gary Phillips

Arovella Therapeutics Limited ( ($AU:ALA) ) has shared an update. Arovella Therapeutics Limited has disclosed that director Gary...

12d ago

Arovella reshapes board as CAR-iNKT cell therapy program advances

Arovella Therapeutics Limited ( ($AU:ALA) ) just unveiled an announcement. Arovella Therapeutics has announced the retirement of Interim...

12d ago

Arovella Steps Up Investor Outreach With Euroz Hartleys Forum and Roadshow

Arovella Therapeutics Limited ( ($AU:ALA) ) has issued an announcement. Arovella Therapeutics announced that CEO and Managing Director...

16d ago

Arovella Wins FDA IND Clearance as It Enters Clinical Stage With CAR-iNKT Cancer Therapy

Arovella Therapeutics Limited ( ($AU:ALA) ) has shared an announcement. Arovella Therapeutics has become a clinical‑stage company after...

16d ago

Arovella Wins FDA IND Clearance for Lead Cell Therapy ALA-101

An announcement from Arovella Therapeutics Limited ( ($AU:ALA) ) is now available. Arovella Therapeutics has received U.S. Food...

23d ago

Arovella Files IND for Lead CAR-iNKT Therapy as Cash Reserves Back 2026 Clinical Push

Arovella Therapeutics Limited ( ($AU:ALA) ) just unveiled an announcement. Arovella Therapeutics reported progress in the second quarter...

29d ago

Arovella Therapeutics Names New Company Secretary and CFO to Support Growth

Arovella Therapeutics Limited ( ($AU:ALA) ) has provided an update. Arovella Therapeutics has appointed Lachie Mallia as Company...

1M ago

Arovella to Release 936,303 Escrowed Shares Issued for Investor Relations Services

Arovella Therapeutics Limited ( ($AU:ALA) ) has provided an update. Arovella Therapeutics has announced that 936,303 ordinary shares,...

1M ago

Arovella Seeks FDA Green Light for First-in-Human Trial of Lead CAR-iNKT Therapy

Arovella Therapeutics Limited ( ($AU:ALA) ) has shared an update. Arovella Therapeutics has submitted an Investigational New Drug...

2M ago

Arovella Therapeutics Issues New Shares to Bolster Cancer Therapy Development

Arovella Therapeutics Limited ( ($AU:ALA) ) has shared an announcement. Arovella Therapeutics Limited has issued 371,187 ordinary shares...

3M ago

ALA FAQ

What was Arovella Therapeutics Limited’s price range in the past 12 months?

Arovella Therapeutics Limited lowest share price was AU$0.07 and its highest was AU$0.20 in the past 12 months.

What is Arovella Therapeutics Limited’s market cap?

Arovella Therapeutics Limited’s market cap is AU$102.61M.

When is Arovella Therapeutics Limited’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Arovella Therapeutics Limited’s earnings last quarter?

Currently, no data Available

Is Arovella Therapeutics Limited overvalued?

According to Wall Street analysts Arovella Therapeutics Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Arovella Therapeutics Limited pay dividends?

Arovella Therapeutics Limited does not currently pay dividends.

What is Arovella Therapeutics Limited’s EPS estimate?

Arovella Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Arovella Therapeutics Limited have?

Arovella Therapeutics Limited has 1,207,183,700 shares outstanding.

What happened to Arovella Therapeutics Limited’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Arovella Therapeutics Limited?

Currently, no hedge funds are holding shares in AU:ALA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Arovella Therapeutics Limited Stock Smart Score

Underperform

Blogger Sentiment

Bullish

AU:ALA Sentiment 93%
Sector Average ―

Technicals

Fundamentals

Return on Equity

-47.98%

Trailing 12-Months

Asset Growth

62.60%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arovella Therapeutics Limited

Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox; invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer; OroMist, an oro-mucosal technology that delivers a range of drug classes through the cheeks, gums, tongue, or floor of the mouth; and Anagrelide to treat cancer. The company also develops oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is headquartered in Osborne Park, Australia.